Compare ZCMD & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZCMD | CGTX |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 79.6M |
| IPO Year | 2019 | 2021 |
| Metric | ZCMD | CGTX |
|---|---|---|
| Price | $0.89 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | ★ 1.5M | 394.7K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.55 |
| 52 Week High | $11.96 | $2.26 |
| Indicator | ZCMD | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 46.19 |
| Support Level | $0.71 | $0.93 |
| Resistance Level | $0.97 | $1.18 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 45.26 | 43.03 |
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).